期刊文献+

奥沙利铂、亚叶酸钙及5-氟尿嘧啶治疗晚期结直肠癌46例 被引量:13

原文传递
导出
摘要 目的探讨奥沙利铂联合亚叶酸钙、5-氟尿嘧啶治疗晚期结直肠癌的临床效果及不良反应。方法选取2011年5月至2013年5月收治的晚期结直肠癌患者46例,均行奥沙利铂+亚叶酸钙+5-氟尿嘧啶治疗,并观察治疗效果。结果治疗后完全缓解6例,部分缓解25例,稳定15例,进展0例,总有效率67.4%。结肠癌与直肠癌患者有效率分别为67.8%、66.7%,二者差异无统计学意义(P>0.05)。患者不良反应主要有呕吐(50.0%)、恶心(47.8%)、血小板减少(54.3%)、神经感觉异常(73.9%)等。均未出现心脏、肝肾功能损害,无化疗相关死亡。结论奥沙利铂联合亚叶酸钙及5-氟尿嘧啶治疗晚期结直肠癌患者效果明显,不良反应发生率低,安全性高,可作为临床治疗晚期结直肠癌的一种有效方法。
作者 刘沛华
出处 《中国临床研究》 CAS 2014年第1期39-40,共2页 Chinese Journal of Clinical Research
  • 相关文献

参考文献7

二级参考文献44

  • 1白桦,郑瑾,王树滨,叶建增,徐敏,许瑞莲,陈亦欣,郑涛.伊立替康或奥沙利铂联合氟尿嘧啶及亚叶酸钙治疗晚期大肠癌[J].肿瘤研究与临床,2008,20(2):120-122. 被引量:2
  • 2孙艳丽,王立波,陈武.伊立替康联合氟尿嘧啶/四氢叶酸治疗晚期大肠癌的临床观察[J].中国肿瘤临床与康复,2007,14(3):251-253. 被引量:6
  • 3De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5 fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol, 1988, 24: 1499- 1503.
  • 4QUASAR Collaborative Group.Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as an adjuvant chemotherapy for colorectal cancer: a randomized trial. Lancet, 2000, 356:1276.
  • 5Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin ) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer, 2006, 94 : 969-975.
  • 6Macdonald JS. Adjuvant therapy of colon cancer. Ca Cancer J Clin, 1999, 49:202-219.
  • 7Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J, 2003, 33:119-124.
  • 8Saris CP, Van de Vaart PJ, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis, 1996, 17:2763-2769.
  • 9Cassidy J, Tabemero J, Twelves C, et al. XELOX ( capecitabine plus oxaliplatin ): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 2004, 22:2084-2091.
  • 10Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase Ⅲ trail conducted in patients with advanced colorectal carcinoma. Eur J Cancer, 2001,37:597-604.

共引文献53

同被引文献99

  • 1Akram Yusup,Hai-Jiang Wang,Azmat Rahmutula,Parhat Sayim,Ze-Liang Zhao,Guo-Qing Zhang.Clinical features and prognosis in colorectal cancer patients with different ethnicities in Northwest China[J].World Journal of Gastroenterology,2013,19(41):7183-7188. 被引量:15
  • 2Karacitin D,Yalcin B,Okten B,et al.Cap ecitabine and oxaliplatin(XELOX)as first-line treatment for patinets with metastatic colorectal cancer[J].J BUON,2009,14(4):605-608.
  • 3Chen J,Huang XF,Qiao L,et al.Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29[J].J Gastrointest Oncol,2011,2(1):27-33.
  • 4Grothey A,Sargent D,Goldbei^ RM,et al.Survival of patients with advanced colorectal cancer improves with the availability of fluorou-racil-leucovorin,irinotecan,and oxaliplatin in the course of treatment[J].J Clin Oncol,2009,22(7):1209-1214.
  • 5Chan RTT,Au GKH,Yau CC,et al.Chemotherapy for advanced colorectal carcinoma:fact and fable[J].Coll Radiol,2010,5(3):143-154.
  • 6Pessino A,Sobrero A.Optimal treatment of metastatic colorectal cancer[J].Expert Rev Anticancer Ther,2011,6(5):801-812.
  • 7Machover D.A comprehensive review of 5-fluorouracil and leuco-vorin in patients with metastatic colorectal carcinoma[J].Cancer,2007,80(7):1179-1187.
  • 8Engstrom PF,Amoletti JP,Benson AB,et al.NCCN Clinical Practice Guidelines in Oncology:Colon Cancer[J].JNCCN,2009,7(8):778-831.
  • 9Engstrom PF,Amoletti JP,Benson AB,et al.NCCN Clinical Practice Guidelines in Oncolc^y:Rectal Cancer[J].JNCCN,2009,7(8):838-881.
  • 10Zalcberg JR,Cunningham D,van Custsem E,et al.ZD1694:a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer[J].J Clin Oncol,2006,14(8):716-721.

引证文献13

二级引证文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部